KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy.

Katherine Bunge, Jennifer E Balkus, Lee Fairlie, Ashley J Mayo, Clemensia Nakabiito, Nyaradzo Mgodi, Luis Gadama, Moleen Matrimbira, Catherine Anne Chappell, Jeanna Piper, Nahida Chakhtoura, Daniel W Szydlo, Barbra Richardson, Sharon L Hillier

J Acquir Immune Defic Syndr 95(1) 65-73

PMID38055292
PMCIDPMC11443417
DOI10.1097/QAI.0000000000003312
发表日期2023-12-06
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Pregnancy represents a period of high HIV acquisition risk. Safety data for the monthly dapivirine vaginal ring (DVR) during pregnancy are limited. Here, we report data from the first 2 cohorts of pregnant participants in MTN-042/DELIVER, a phase 3b, randomized, open-label safety trial of DVR and oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC). MTN-042 is being conducted in 3 cohorts beginning with later gestational ages when risks of drug exposure are less. METHODS: Eligible pregnant individuals aged 18-40 years in Malawi, South Africa, Uganda, and Zimbabwe were randomized 2:1 to monthly DVR or daily TDF/FTC. Participants in cohort 1 initiated product use between 36 weeks 0 days (36 0/7 weeks) and 37 6/7 weeks gestation; participants in cohort 2 initiated product use between 30 0/7 and 35 6/7 weeks gestation. All participants continued product use until delivery or 41 6/7 weeks gestation. Pregnancy outcomes and complications were assessed and summarized using descriptive statistics and compared with local background rates obtained through a separate chart review. RESULTS: One-hundred and fifty participants were enrolled into cohort 1 with 101 randomized to DVR and 49 to TDF/FTC. One-hundred and fifty-seven participants were enrolled into cohort 2 with 106 randomized to DVR and 51 to TDF/FTC. In both cohorts, pregnancy complications were rare and similar to local background rates. CONCLUSION: In this first study of a long-acting HIV prevention agent in pregnancy, adverse pregnancy outcomes and complications were uncommon when DVR and TDF/FTC were used in the third trimester of pregnancy, suggesting a favorable safety profile for both prevention products.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。